Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists investigate why high 'Bad' cholesterol harms heart repair cells

NCT ID NCT06626659

Knowledge-focused Sponsor: Canadian Medical and Surgical Knowledge Translation Research Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study examined blood samples from 40 adults to see if high levels of lipoprotein (a), a type of cholesterol, are linked to fewer or different blood vessel repair cells. Participants with high Lp(a) were compared to those with normal levels. The goal was to better understand how Lp(a) might contribute to heart disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could reveal why high lipoprotein (a) harms heart health, pointing toward new ways to prevent or treat cardiovascular disease.
What could go wrong
This is a small, observational study that only measures cells in blood samples. It does not test any treatment, so it may not lead to direct patient benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

40 people

The number who actually took part.

Started

Oct 2024

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be identified from primary care and cardiology outpatient clinics in the Greater Toronto Area using paper-based and electronic medical records.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults ≥18 years of age and ≤80 years of age who meet either of the following criteria: 1. Elevated Lp(a) (defined as greater than or equal to 100 nmol/L) 2. Non-elevated Lp(a) (defined as less than 100 nmol/L) 2. Willing and able to provide written informed consent and comply with study procedures. Exclusion Criteria: 1. Unable or unwilling to provide written informed consent or provide a peripheral blood sample. 2. Any life-threatening disease expected to result in death within two years of consent. 3. Any malignancy not considered cured (except basal cell carcinoma of the skin). An individual is considered cured if there has been no evidence of cancer recurrence for the five years prior to screening. 4. Uncontrolled hypertension. 5. New York Heart Association Class IV heart failure. 6. Active liver disease or liver dysfunction. 7. Active kidney disease or kidney dysfunction. 8. History of hemorrhagic stroke or other major bleeding disorder. 9. White blood cell count ≥15 x 10\^9/L. 10. Women who are pregnant or nursing. 11. Previously received ribonucleic acid therapy specifically targeting Lp(a). 12. Active infectious disease requiring systemic antibiotic or anti-viral agents. 13. Known acquired immunodeficiency syndrome, such as human immunodeficiency virus. 14. On oral steroid therapy (e.g., prednisone or other corticosteroids) or other immunosuppressive agents (e.g., methotrexate). 15. Treated autoimmune disorders. 16. Participating in another study/trial that is likely to affect the primary outcome.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherosclerosis cardiovascular disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atherosclerotic cardiovascular disease cardiovascular disorder Dyslipidemias inherited lipid metabolism disorder myocardial ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atherosclerosis cardiovascular disease Cardiovascular diseases Dyslipidemia Ischemic heart disease

Contacts and locations

Locations

  • Diagnostic Assessment Centre

    Scarborough Village, Ontario, M1S4N6, Canada

  • North York Diagnostic and Cardiac Centre

    North York, Ontario, M6B1N6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.